0000950170-23-064914.txt : 20231117 0000950170-23-064914.hdr.sgml : 20231117 20231117173008 ACCESSION NUMBER: 0000950170-23-064914 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231115 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20231117 DATE AS OF CHANGE: 20231117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 231420115 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 8-K 1 virx-20231115.htm 8-K 8-K
0001061027falseViracta Therapeutics, Inc.00010610272023-11-152023-11-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2023

 

 

VIRACTA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51531

94-3295878

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2533 S. Coast Hwy. 101, Suite 210

 

Cardiff, California

 

92007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 400-8470

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VIRX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 3.01. Results of Operations and Financial Condition

On November 15, 2023, Viracta Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 13, 2024, to regain compliance with the Minimum Bid Price Requirement. The Notice states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(a)(2) if, at any time before May 13, 2024, the closing bid price of the Company’s common stock is $1.00 per share or more for a minimum of ten consecutive business days. The Notice has no immediate effect on the listing or trading of the Company’s common stock.

In the event the Company does not regain compliance with the Minimum Bid Price Requirement by May 13, 2024, the Company may be eligible for additional time to regain compliance. To qualify, the Company must submit an application to transfer to The Nasdaq Capital Market, which would require the Company to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Company will be granted an additional 180 calendar days to regain compliance. If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Nasdaq staff will provide written notification to the Company that its common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel.

The Company intends to actively monitor the closing bid price of its common stock and consider its available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day compliance period ending May 13, 2024, secure an extension of the compliance period beyond May 13, 2024, or maintain compliance with any other Nasdaq listing requirements.

 

Forward-Looking Statements

Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company’s ability to

regain compliance with the Minimum Bid Price Requirement, the Company’s intentions to actively monitor the closing bid price of its

common stock, and the Company’s plans to consider implementing available options to regain compliance with the Minimum Bid

Price Requirement. Actual results or developments may differ materially from those projected or implied in these forward-looking

statements. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” in

the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023. You are cautioned not to place undue

reliance on forward-looking statements which are current only as of the date hereof. Except as required by applicable law, the

Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking

statements, whether as a result of new information, future events or otherwise.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Viracta Therapeutics, Inc

 

 

 

 

Date:

November 17, 2023

By:

/s/ Daniel Chevallard

 

 

 

Daniel Chevallard
Chief Operating Officer and Chief Financial Officer

 

 EX-101.SCH 2 virx-20231115.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 virx-20231115_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 virx-20231115_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 15, 2023
Entity Registrant Name Viracta Therapeutics, Inc.
Entity Central Index Key 0001061027
Entity Emerging Growth Company false
Securities Act File Number 000-51531
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3295878
Entity Address, Address Line One 2533 S. Coast Hwy. 101, Suite 210
Entity Address, City or Town Cardiff
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92007
City Area Code (858)
Local Phone Number 400-8470
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol VIRX
Security Exchange Name NASDAQ
XML 6 virx-20231115_htm.xml IDEA: XBRL DOCUMENT 0001061027 2023-11-15 2023-11-15 0001061027 false Viracta Therapeutics, Inc. 8-K 2023-11-15 DE 000-51531 94-3295878 2533 S. Coast Hwy. 101, Suite 210 Cardiff CA 92007 (858) 400-8470 false false false false Common Stock, par value $0.0001 per share VIRX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports virx-20231115.htm virx-20231115.xsd virx-20231115_lab.xml virx-20231115_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "virx-20231115.htm": { "nsprefix": "virx", "nsuri": "http://viracta.com/20231115", "dts": { "inline": { "local": [ "virx-20231115.htm" ] }, "schema": { "local": [ "virx-20231115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "virx-20231115_lab.xml" ] }, "presentationLink": { "local": [ "virx-20231115_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_8614a47b-c1b3-4b64-a95a-ce5b3e37572b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20231115.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8614a47b-c1b3-4b64-a95a-ce5b3e37572b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20231115.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://viracta.com/20231115/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-23-064914-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-064914-xbrl.zip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